[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

La Merie Publishing: Market Research Reports

Set up in 2002, La Merie Publishing is an authoritative supplier of the cutting-edge information on the biopharmaceutical industry, with a special focus on the research and development pipeline and covering issues related to biologics, including peptides, antibodies, DNA, RNA, proteins and cell therapy.

The company’s service portfolio is represented by various formats and price levels, and includes Brief Reports, Full Reports and Competitor Analysis Reports. Competitor Analysis Reports present no frills, but accurate data on the pipeline of research and development projects for diseases, targets, companies and technologies. The data are fully referenced and delivered in a tabular format. Brief Reports covering Target Pipelines contain all-round assessments of both business and scientific perspectives of new targets. Full Reports present deep analyses of product portfolios, competitive landscape, R&D pipelines and discussions of the pipeline perspectives.

Publications found: 223
Sort by:
Competitor Analysis: B7 – CD28/CTLA-4 Pathway US$ 370.00

... /CTLA-4 signaling family to treat autoimmune diseases or cancer. In addition, the report lists company-specific R&D pipelines of projects in the B7 – CD28/CTLA-4 pathway. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound ...

July 2012 35 pages
Competitor Analysis: Dengue Virus Vaccines and Therapeutics US$ 243.00

... of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...

July 2012 27 pages
Competitor Analysis: Interleukin-1 (IL-1) Inhibitors and IL-1 Receptor (IL-1R) Antagonists US$ 182.00

... for treatment of rheumatoid arthritis, diabetes, gout, COPD and other autoimmune/inflammatory conditions provides a competitor evaluation in the field of R&D projects with Interleukin-1 (IL-1) Inhibitors and Receptor (IL-1R) Antagonists as of July 2012. Purchase of the downloadable pdf report includes a 6- ...

July 2012 22 pages
Competitor Analysis: RSV Vaccines and Therapeutics US$ 315.00

Competitor Analysis: Respiratory Syncytial Virus (RSV) Vaccines and Therapeutics The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a ... RSV disease in infants and children at high risk for severe lung disease from RSV, a RSV vaccine still is not on the market. A number ...

June 2012 30 pages
Competitor Analysis: Janus Kinase (JAK) Inhibitors US$ 394.00

... Report about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of active R&D projects from ... have been identified: JAK1, JAK2, JAK3 and tyrosine kinase 2 (Tyk2). JAK3 has attracted much attention as an anti-inflammatory drug target ...

May 2012 44 pages
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics US$ 394.00

The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules as well as DNA-, RNA- and microorganism-based therapies against infection with ...

May 2012 46 pages
Competitor Analysis: Immunotherapy of Alzheimer's Disease US$ 500.00

Competitor Analysis: Immunotherapy of Alzheimer’s Disease The Competitive Intelligence Report Immunotherapy of Alzheimer’s Disease as of May 2012 provides a competitor analysis in the development pipeline of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer’s disease including ...

May 2012 42 pages
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012 US$ 2,600.00

This report “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012” published in March 2012 provides a compilation ... market. The unique feature of weight reduction associated with the use GLP-1R agonists clearly differentiates this antidiabetic drug class from other ...

March 2012 231 pages
Competitor Analysis: Anti-Obesity Peptides and Biologics US$ 262.00

... peptides and biologics as of February 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and ... . In addition, the report lists company-specific R&D pipelines of anti-obesity peptides and biologics. Competitor projects are listed in a tabular format providing ...

February 2012 28 pages
Competitor Analysis: HIV Small Molecule Therapeutics US$ 642.00

The present Competitive Intelligence report about HIV Small Molecule Therapeutics used to treat human immunodeficiency virus (HIV) infections provides a competitor evaluation in the field of marketed...

December 2011 100 pages
Competitor Analysis: Anti-Infective Antibodies US$ 1,086.00

Product description The present Competitive Intelligence Report about Anti-Infective Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies and human plasma-derived immunoglobulins and hyperimmunes for post-exposure prophylaxis and treatment of ...

November 2011 160 pages
Vaccine Pipeline Database: 1-Year Subscription US$ 1,333.00

Subscription to La Merie’s proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use ...

October 2011 274 pages
Competitor Analysis HIV Vaccines US$ 413.00

... (plasmid, conventional, alternative delivery and prime – boost regimens) Adenoviral vector vaccines Poxvirus vector vaccines Protein & peptide vaccines Others Corporate HIV Vaccine R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise ...

October 2011 54 pages
Coagulation Factors 2011 – Who Does Meet the Market Needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis US$ 3,258.00

Product description The report “Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate ... engineering and drug delivery technologies overview and analysis of marketed coagulation factors; market research study with haematologists from haemophilia care ...

October 2011 162 pages
Competitor Analysis: Novel Mitotic Kinase Inhibitors US$ 550.00

... cell cycle, whereas CDK7 has dual roles as a CDK-activating kinase (CAK) and a regulator of the transcriptional machinery. CDK8 and CDK9 ... Inhibitors Corporate Novel Mitotic Kinase Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, ...

September 2011 62 pages
Competitor Analysis: Her2 and Her3 Receptor Antagonists US$ 413.00

... active projects in research and development of molecules targeting the Her2 (ErbB2) and Her3 receptor. In addition, the report lists company-specific ... Antagonists Pan-Her Receptor Antagonists Corporate Her2 and Her3 Receptor Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The ...

September 2011 63 pages
Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis US$ 2,632.00

... Product description This report “Antibody-Drug Conjugates 2011 – real breakthrough still to come: A Technology, Stakeholder and R&D Pipeline Analysis” published in September ... still narrow the therapeutic window for the currently used drugs and linkers. Nevertheless, about half of the currently clinical stage ...

September 2011 274 pages
Competitor Analysis: EGF-R Agonists and Antagonists US$ 533.00

... -R and Her2 Receptor Antagonists Pan-ErbB (pan-Her) Receptor Antagonists Multi-Target EGF-R Antagonists Others Corporate EGF-R Agonist and Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about ...

September 2011 73 pages
Competitor Analysis: Targeted Therapy of Hepatitis C US$ 826.00

Product description The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online ...

August 2011 91 pages
Competitor Analysis: Heat shock protein 90 (Hsp90) Inhibitors US$ 275.00

... The present Competitive Intelligence report about Heat shock protein 90 (Hsp90) Inhibitors provides a competitor evaluation in the field of novel small molecules ... database will be sent by e-mail and allow online work with the project data to print or export an individual report. Inhibition of heat shock ...

July 2011 26 pages
Competitor Analysis: HDAC Inhibitors US$ 550.00

... the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Histone deacetylase (HDAC) ... class I and II Inhibitors Multi-Target HDAC Inhibitors Others Corporate HDAC Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The ...

July 2011 58 pages
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors US$ 660.00

... other pathywas such as the PI3K-Akt-mTOR pathways. Combining a mutant B-Raf inhibitor with a targeted T-cell antibody, such as ipilimumab, may increase ... ERK Pathway Corporate Ras-Raf-MEK-ERK Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers ...

June 2011 75 pages
Competitor Analysis: Hepatitis Vaccines US$ 498.00

... Vaccines Combination Vaccines including HAV Vaccines Combination Vaccines including HBV Vaccines Hepatitis C Virus Vaccines Hepatitis E Virus Vaccines Corporate Hepatitis Vaccine Product Portfolios and R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but ...

June 2011 96 pages
Competitor Analysis: PI3K-AKT-mTOR Inhibitors US$ 711.00

... effort has gone into developing agents that inhibit one or more PI3K isoforms, e.g. alpha and beta, as well as closely related proteins implicated in ... Others Corporate PI3K-AKT-mTOR Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, ...

June 2011 100 pages
Competitor Analysis: IGF-1R Antagonists US$ 275.00

... -1/R antagonists Small Molecule Multi-target IGF-1/R antagonists Biologics as Selective IGF-1/R antagonists Biologics as Dual IGF-1/R antagonists Corporate IGF-1R Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise ...

June 2011 26 pages
Competitor Analysis Influenza Vaccines US$ 718.00

... of seasonal and pandemic influenza disease. In addition, the report lists company-specific product portfolios and R&D pipelines of influenza vaccines on the market and in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of ...

May 2011 123 pages
Competitor Analysis: Emerging Diabetes Drugs US$ 870.00

Product description The present Competitive Intelligence Report about Emerging Diabetes Drugs provides a competitor evaluation in the field of novel molecules against a series of novel targets being developed for treatment of type 1 or 2 diabetes as of April 2011. Pharmacologic approaches include SGLT ...

April 2011 104 pages
Competitor Analysis: Targeted Therapy of Diabetes US$ 1,735.00

Product description The present Competitive Intelligence Report about Targeted Therapy of Diabetes provides a competitor evaluation in the field of novel molecules being developed for treatment of type 1 and 2 diabetes as of April 2011. Major pharmacologic approaches include insulin, PPAR agonists, DPP-IV ...

April 2011 114 pages
Competitor Analysis: Adenosine Receptor Agonists & Antagonists US$ 287.00

... and development of novel adenosine receptor agonists & antagonists. In addition, the report lists company-specific R&D pipelines of adenosine receptor agonists & antagonists in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, ...

April 2011 26 pages
Competitor Analysis RNA Therapeutics in Clinical Development US$ 561.00

... online work with the project data to print or export an individual report. Although there are only two approved and marketed RNA based ... CpG Oligonucleotides Corporate Clinical Stage RNA Therapeutics R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but ...

March 2011
Competitor Analysis: Targeted Therapy of Obesity US$ 706.00

... aminopeptidase 2 (MetAP2) Inhibitors f) Other Metabolic Modifiers 6) Various Approaches 7) Unspecified Targets Corporate Targeted Therapy of Obesity R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D ...

March 2011 80 pages
RNA Therapeutics Pipeline Database: 1-Year Subscription US$ 847.00

... (RNAi) or Locked Nucleic Acid (LNA) RNA. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of ... illustrate the database. Purchase of the subscription provides a 1-year online access to the data of the RNA Therapeutics Pipeline Database. Credentials to access ...

March 2011
Competitor Analysis Interferon US$ 619.00

Product description The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural interferon alpha, beta, gamma, lambda and of other subtypes for treatment of hepatitis B and C, other ...

February 2011 89 pages
Competitor Analysis: Cancer Antibodies in Early Clinical Development US$ 1,210.00

... CD20, VEGF and Her2, but also of many new and unique antibodies directed against novel targets which will have to show its ... cancer. In addition, the report lists company-specific R&D pipelines of anti-cancer antibodies. Competitor projects are listed in a tabular format providing information on: Drug Codes, ...

February 2011 183 pages
Therapeutic Protein Pipeline Database: 1-Year Subscription US$ 1,613.00

... order, e.g. for phase, product category or company name. Sample screenshots illustrate the database. Purchase of the subscription provides a 1-year online access to the data of the Therapeutic Protein Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase ...

February 2011
Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO-IL-11) US$ 259.00

The Competitive Intelligence Report Thrombopoiesis Stimulating Agents (TPO; IL-11) as of January 2011 provides information on thrombopoiesis stimulating agents targeting the thrombopoietin, interleukin-11 or other receptors on the market and in development. In addition, the report lists company-specific R&D ...

January 2011 21 pages
Competitor Analysis: G-CSF & GM-CSF US$ 454.00

... report includes a compilation of currently marketed branded and non-branded G-CSF and GM-CSF products in regulated and non-regulated markets for treatment ... products in regulated markets 1st and next generation GM-CSF products in non-regulated markets About La Merie About Competitor Analysis Series: The ...

January 2011 40 pages
Competitor Analysis: Erythropoietin (EPO) US$ 684.00

Product description The Competitive Intelligence Report Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) as of January 2011 in its 5th edition provides information on existing first and second generation epoetin products in regulated markets, an overview on biosimilar versions of EPO in ...

January 2011 76 pages
Competitor Analysis: Insulin US$ 616.00

Product description The Competitive Intelligence Report Insulin as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant insulin and insulin analogs for the treatment of type 1 and type 2 diabetes mellitus. Purchase of the pdf report includes ...

January 2011 73 pages
Competitor Analysis Antibody Therapy of Inflammatory and Autoimmune Diseases US$ 1,184.00

Product description The present Competitive Intelligence Report about Antibody Therapy of Inflammatory and Autoimmune Diseases provides a competitor evaluation in the field of antibody therapeutics used or being developed for treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis ...

December 2010 172 pages
Competitor Analysis: Sphingosine-1-Phosphate (S1P) US$ 277.00

Product description The present Competitive Intelligence Report about Sphingosine-1-Phosphate (S1P) provides a competitor evaluation in the field of molecules interacting with the sphingosine-1-phosphate pathway as of November 2010. Among these molecules are S1P and selective S1P1 receptor agonists or S1P ...

November 2010 26 pages
Antibody Technology Companies 2010 - A systematic guide through the landscape of antibody technologies and their providers US$ 1,394.00

The report “Antibody Technology Companies 2010 – A systematic guide through the landscape of antibody technologies and their providers” provides a description and ... range of possibilities, the selection of the most robust and adequate technologies fitting fitting to the product target profile has become more ...

November 2010 283 pages
Antibody Pipeline Database: 1-Year Subscription US$ 1,638.00

... numerical order, e.g. for phase, product category or company name. Sample screenshots illustrate the database. Purchase of the subscription provides a 1-year online access to the data of the Antibody Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase. ...

November 2010
Competitor Analysis p38 MAPK Inhibitors US$ 273.00

... would be expected to decrease the production of these cytokines. About ten p38 MAPK inhibitors are in clinical phase I and II studies, with the first ... leading to the source of information. Index p38 MAPK Inhibitors p38 alpha MAPK Inhibitors About La Merie About Competitor Analysis Series: The ...

November 2010 21 pages
Competitor Analysis Interleukin-6 (IL-6) and Receptor (IL-6R) Antagonists US$ 205.00

... IL-6R Antagonists in Inflammation IL-6 and IL-6R Antagonists in Oncology Small Molecule Approaches of IL-6 and IL-6R Antagonists About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, ...

November 2010 20 pages
Competitor Analysis: Biosimilar and Biobetter/Biosuperior Antibodies US$ 961.00

Product description The present Competitive Intelligence Report about Biosimilar and Biobetter/Biosuperior Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyc...

October 2010 106 pages
Competitor Analysis Toll-Like Receptor (TLR) Agonists & Antagonists US$ 800.00

... description The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists provides a competitor analysis in the development pipeline of novel small ... with the project data to print or export an individual report. Toll-like receptors (TLRs) are a class of proteins that play a key role ...

October 2010 144 pages
Competitor Analysis: C5a-R Antagonists US$ 173.00

... , Target / Mechanism of Action, Class of Compound, Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. Index C5 Antagonists C5a Antagonists C5aR Antagonists Corporate C5a & C5aR Antagonist R&D Pipelines About La Merie

October 2010 14 pages
Coagulation Factors 2010 – The Portfolio Aspect as Decisive Force: A Competitive Landscape and R&D Pipeline Analysis of Hemostasis Proteins US$ 3,346.00

Product description The report “Coagulation Factors 2010 - The Portfolio Aspect as Decisive Force: A Competitive Landscape and R&D Pipeline Analysis of Hemostasis Proteins” ... but also newcomers to the field are developing more than one factor. Portfolio not only means the addition of a second or even third ...

September 2010 446 pages
Competitor Analysis: Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease US$ 890.00

Product description The present Competitive Intelligence Report about Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease provides a competitor evaluation in the field of therapeutic vaccine...

August 2010 105 pages

Filters

Search

Categories

2
1
1
4
1
19
27
3
2
1
10
4
21
5
5
100
17

Publishers

223

Regions

223

Price

Date

Pages

Offers

1
4